Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

Antidepressants not linked to worse early outcomes after traumatic brain injury

Taking certain antidepressants at the time of a traumatic brain injury (TBI) is not associated with an increased risk of ...
pharmaphorum

Otsuka preps for July decision on centanafadine for ADHD

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...
News-Medical.Net

Antidepressant use does not worsen early outcomes after traumatic brain injury

Taking certain antidepressants at the time of a traumatic brain injury (TBI) is not associated with an increased risk of ...
Becker's Hospital Review

FDA fast-tracks ADHD drug for priority review

The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...
Healio

Viloxazine with or without trazodone decreases OSA severity

Please provide your email address to receive an email when new articles are posted on . Viloxazine is a noradrenergic/norepinephrine reuptake inhibitor, and trazodone ...